ENTER


Полный размерЗакрыть

Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension

Details
Written by Super User
Category: #2 (07) 2017
Published: 18 April 2018
Hits: 1735

Michele Iester

Clinica Oculistica, University of Genoa, Genova, Italy 

 Summary. Brinzolamide is a white powder commercially formulated as a 1 % ophthalmic. Suspension to reduce intraocular pressure (IOP). Pharmacologically, brinzolamide is a highly specific, non-competitive, reversible, and effective inhibitor of carbonic anhydrase II (CA-II), able to suppress formation of aqueous humor in the eye and thus to decrease IOP. Several clinical trials have evaluated its safety and the most commonly ocular adverse events are blurred vision (3–8 %), ocular discomfort (1.8–5.9 %), and eye pain (0.7–4 %). Brinzolamide has been introduced to treat ocular hypertension and primary open-angle glaucoma. In some clinical studies it has been estimated that brinzolamide reduced IOP by was about 18 %. Brinzolamide can be added to beta-blockers and prostaglandins. In the latter combination, because prostaglandin derivatives improve the uveoscleral outflow but also increase the activity of CA in ciliary epithelium with a secondary increase in aqueous humor secretion, and slightly reduce the efficacy of prostaglandin analogues, theoretically topical CA inhibitors (CAI) decrease IOP by inhibiting CA-II, thus improving prostaglandin efficacy as well as lowering IOP. Brinzolamide could have a secondary possible effect on ocular flow too. Some clinical studies showed a mild improvement of ocular blood flow. Theoretically, CAI could give rise to metabolic acidosis, with secondary vasodilatation and improvement of blood flow. Systemic acidosis can occur in the setting of oral CAI therapy, and local acidosis within ocular tissues is theoretically possible with topical CAI therapy, with the potential for a local increase in ocular blood flow. In conclusion, topical CAI treatment has efficacy in IOP-lowering ranging from 15 % to 20 %. From published data, brinzolamide can be used as first-line medication, even if other medications have a higher efficacy, with few side effects and it is a good adjunctive treatment. In some type of glaucoma patients with a vascular dysregulation, topical CAI could have a double effect: reducing IOP and improving ocular blood flow.

 Keywords: brinzolamide, ocular hypertension, glaucoma, intraocular pressure, ocular blood flow, safety, treatment.

REFERENCES

  1. Adamson I. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;128:774–5.
  2. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–40.
  3. Barnes GE, Wilhelm F, Schoch C. Increased optic nerve head blood flow after 1 week of twice daily topical brinzolamide treatment in Dutch-belted rabbits. Surv Ophthalmol. 2000; 44:131–40.
  4. Bonomi L, Marchini G, Maraffa M, et al. Vascular risk factors for primary open angle glaucoma. Ophthalmology. 2000;107:1287–93.
  5. Budenz DL, Anderson DR, Feuer WJ, et al. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. Ophthalmology. 2006; 113:2137–43.
  6. Carlsson AM, Chauhan BC, Lee AA, et al. The effect of brimonidinetartrate on retinal blood flow in patients with ocular hypertension. Am J Ophthalmol. 2006;129:297–301.
  7. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998; 126:498–505.
  8. Costa VP, Harris A, Stefansson E, et al. The effects of antiglaucomatous and systemic medications on ocular blood flow. Progr Retin Eye Res. 2003;22:769–805.
  9. Cvetkvic RS, Perry CM. Brizolamide. A review of its use in the management of Primary open-angle glaucoma and ocular hypertension. Drug Aging. 2003;20:919–47.
  10. DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000;44(Suppl 2): S119–S129.
  11. European Glaucoma Society. Terminology and Guidelines. Savona: Dogma. 2003.
  12. Faraci FM, Heistad DD, Mayham WG, et al. Role of larger arteriesin regulation of blood flow to the brain stem in cats. J Physiol. 1987;387:112–5.
  13. Feldman RM, Tanna AP, Gross RL, et al. Comparison of the ocularhypotensive effi cacy of adjunctive brimonidine 0.15 % or brinzolamide 1 % in combination with travoprost 0.004 %. Ophthalmology. 2007;114:1248–54.
  14. Franks W. Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1 % added to travoprost ophthalmic solution 0.004 % therapy in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2006;22:1643–9.
  15. Galassi F, Nuzzaci G, Sodi A, et al. Color Doppler imaging in evaluationof optic nerve blood supply in normal and glaucomatous subjects. Int Ophthalmol. 1992;16:273–6.
  16. Gherghel D, Orgul S, Gugleta K, et al. Relation between ocular perfusion and retrobulbar blood flow in patients with glaucoma with progressive damage. Am J Ophthalmol. 2000; 130:597–605.
  17. Grieshaber MC, Mozaffarieh M, Flammer J. What is the link between vascular dysregulation and glaucoma? Surv Ophthalmol. 2007;52(2):144–54.
  18. Harris A, Arend O, Arend S, et al. Effects of topical dorzolamide on retinaland retrobulbar hemodynamics. Acta Opthalmol Scand. 1996;74:569–72.
  19. Harris A, Arend O, Kagemann L, et al. Dorzolamide, visual functionand ocular hemodynamics in normal tension glaucoma. J Ocular PharmTher. 1999;15:189–97.
  20. Hauge A, Nicolaysen G, Thoresen M. Acute effects of acetazolamide on cerebral blood flow in man. Acta Physiol Scand. 1983;117:233–9.
  21. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early ManifestGlaucoma Trial. Arch Ophthalmol. 2002;120: 1268–79.
  22. Hollo G, Chiselita D, Petkova N, et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added totravoprost in patients with ocular hypertension or primary open-angleglaucoma. Eur J Ophthalmol. 2006;16:816–23.
  23. Iester M, Altieri M, Michelson G, et al. Retinal peripapillary blood flow before and after topical brinzolamide. Ophthalmologica. 2003;218:390–6.
  24. Iester M. Brinzolamide. Expert Opin Pharmacother. 2008;9:653–62.
  25. Ingram CJ, Brubaker RF. Effect of brinzolamide and dorzolamide onaqueous humor flow in human eyes. Am J Ophthalmol. 1999;128:292–6.
  26. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.
  27. Kaup M, Plange N, Niegel M, et al. Effects of brinzolamide on ocularhaemodynamics in healthy volunteers. Br J Ophthalmol. 2004;88:257–62.
  28. Kaur IP, Smitha R, Deepika A, et al. Acetazolamide: future perspectivein topical glaucoma therapeutics. Int J Pharm. 2002;248:1–14.
  29. Konowal A, Morrison JC, Brown SVL, et al. Irreversible corneal decompansation in patients treated with topical dorzolamide. Am J ophthalmol. 1999;127:403–6.
  30. Kothy P, Hollo G. Does glaucoma medication influence the diameter of the retinal arteriole in the human eyes? (A pilot study using the retinalvessel analyser). Aca Phisiol Hungarica. 2001;88:281–92.
  31. Leske MC, Connell AM, Wu SY, et al. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol. 1995;113:918–24.
  32. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48–56.
  33. Leske MC, Heijl A, Hyman L, et al. EMGT Group. Predictorsof long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965–72.
  34. March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0 % (azopt) in patients with primary open-angle glaucoma orocular hypertension. The Brinzolamide LongTerm Therapy Study Group. Am J Ophthalmol. 2000;129:136–43.
  35. Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev. 1967; 47:595–781.
  36. Martinez-de-la-Casa JM, Castillo A, Garcia-Feijoo J, et al. Concomitant administration of travoprost and brinzolamide versus fixedlatanoprost/timolol combined therapy: three-month comparison of efficacy and safety. Curr Med Res Opin. 2004;20:1333–9.
  37. Menon GJ, Vernon SA. Topical brinzolamide and metabolic acidosis. Br J Ophthalmol. 2006;90:247–8.
  38. Michaud JE, Friren B. Comparison of topical brinzolamide 1 % anddorzolamide 2 % eye drops given twice daily in addition to timolol 0.5 % in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:235–43.
  39. Nakamoto K, Yasuda N. Effect of concomitant use of latanoprost and brinzolamide on 24- hour variation of IOP in normal-tension glaucoma. J Glaucoma. 2007;16:352–7.
  40. Nicolela MT, Drance SM. Various glaucomatous optic nerve appearances: clinical correlations. Ophthalmology. 1996;103:640–9.
  41. Pederson JE, Anderson DR. The mode of progressive disc cupping inocular hypertension and glaucoma. Arch Ophthalmol. 1980;98:490–5.
  42. Quigley HA, West SK, Rodriguez J, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119:1819–26.
  43. Reis R, Queiroz CF, Santos LC, et al. A randomized, investigatormasked, 4-week study comparing timolol maleate 0.5 %, brinzolamide 1 %, and brimonidine tartrate 0.2 % as adjunctive therapies to travoprost 0.004 % in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28:552–9.
  44. Ringelstein EB, Van Eyck S, Mertens I. Evaluation of cerebral vasomotor reactivity by various vasodilating stimuli: comparison of CO2 to acetazolamide. J Cerebral Blood Flow. 1992;12:162–8.
  45. Sall K. The efficacy and safety of brinzolamide 1 % ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol. 2000;44(2):155–162.
  46. Sampaolesi J, Tosi J, Darchuk V, et al. Antiglaucomatous drugs effects on optic nerve head flow: design, baseline and preliminary report. Int Ophthalmol. 2001;23:359–67.
  47. Schulzer M, Drance SM. Intraocular pressure, systemic blood pressure, and age: a correlational study. Br J Ophthalmol. 1987;71:245–9.
  48. Severinghaus JW, Cotev S. Carbonic acidosis and cerebral vasodilatation after diamox. Scand J Clin Lab Invest. 1968;22:1E.
  49. Shin D. Adjunctive therapy with brinzolamide 1 % ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol. 2000;44(2):163–168.
  50. Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1 % as adjunctive therapy to latanoprost 0.005 % in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin. 2005;21:503–8.
  51. Shoji N. Brinzolamide: efficacy, safety and its role in the management of glaucoma. Expert Rev Ophthalmol. 2007;2:695–704.
  52. Siesky B, Lin T, Kagemann L, et al. Comparison of three months treatment with dorzolamide and brinzolamide on perfusion pressuresin primary open angle glaucoma patients. 6th International Symposium on Ocular Pharmacology and Therapeutics; 2006 March 30 −Apr 2; Berlin, Germany. Berlin; 2006.
  53. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol. 1998;126:400–8.
  54. Silver LH. Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide Dose-Response Study Group. Surv Ophthalmol. 2000;44(2):147–53.
  55. Sponsel WE, Shipman DL. The role of blood gases in ocular perfusion. In: Drance S, Chauhan B, editors. Ocular blood flow. Amsterdam: Kugler; 1997. Vol. 3.
  56. Tielsch JM, Katz J, Sommer A, et al. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol. 1995;113:216–21.
  57. Van der Valk R, Webers CAB, Schouten JSAG, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs. A metaanalysis of randomized clinical trials. Ophthalmology. 2005;112:1177–85.
  58. Volstrup S, Henriken L, Paulson DB. Effect of acetazolamide on cerebral blood flow and cerebral metabolic rate oxigen. J Clin Invest. 1984;74:1634–9.
  59. Wang TH, Huang JY, Hung PT, et al. Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. J Formos Med Assoc. 2004;103:369–73.
  60. Zeyen TG, Caprioli J. Progression of disc and field damage in early glaucoma. Arch Ophthalmol. 1993;111:62–5.
  61. Zhao JC, Chen T. Brinzolamide induced reversible corneal decompensation. Br J Ophthalmol. 2005;89:389–90.

Received: 30 Aug. 2017

Published: December 2017